MedPath

Deep Learning in Retinoblastoma Detection and Monitoring.

Conditions
Retinoblastoma
Registration Number
NCT05308043
Lead Sponsor
Beijing Tongren Hospital
Brief Summary

Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. In the current study, we develop a deep learning algorism that can simultaneously identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. This algorism will be validated through a prospectively collected dataset.

Detailed Description

Retinoblastoma, the most common eye cancer of childhood, affects 1 in 15 000 to 1 in 18 000 live births. China has the second-largest number of patients with retinoblastoma in the world. Eye-preserving therapies have been used widely in China for approximately 15 years. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. However, the major amount of qualified ophthalmologists are concentrated in several medical centres. Deep learning based on Retcam examination that can identify retinoblastoma will reduce screening accuracy of the local hospitals and reduce monitoring wordload. In the current study, a deep learning algorism was developed that can simultaneously identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. This algorism will be validated through a prospectively collected dataset.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Retinoblastoma patients undergo standard medical management.
Exclusion Criteria
  • The operators identified images non-assessable for a correct diagnosis, due to reasons such as blur and defocus, and excluded them from further analysis.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diagnosis accurcy of deep learning algorism1 week

The diagnosic accurcy of this deep learning algorism is the proportion of true positive and true negative in all evaluated cases

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Wen-Bin Wei

🇨🇳

Beijing, Beijing, China

Wen-Bin Wei
🇨🇳Beijing, Beijing, China
Wen-Bin Wei, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.